Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis

Cytokine

Volumn 50, Issue 2, 2010, Pages 181-185

  Owczarek, Witold ^a   Paplińska, Magdalena ^b   Targowski, Tomasz ^a   Jahnz Royk, Karina ^a   Paluchowska, Elwira ^a   Kucharczyk, Aleksandra ^a   Kasztalewicz, Beata ^c  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Atopic dermatitis; Chemokines; Eotaxin 1 CCL11; Eotaxin 2 CCL24; Eotaxin 3 CCL26

Indexed keywords

EOTAXIN; EOTAXIN 2; EOTAXIN 3;

ADULT; AMINO ACID SEQUENCE; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ECZEMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SKIN BIOPSY; SKIN DEFECT;

ADULT; CASE-CONTROL STUDIES; CHEMOKINE CCL11; CHEMOKINE CCL24; CHEMOKINES, CC; DERMATITIS, ATOPIC; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; YOUNG ADULT;

EID: 77950917900     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.02.016     Document Type: Article

References (46)

1. Buggiani G., Ricceri F., Lotti T. Atopic dermatitis. Dermatol Ther 2008, 21:96-100.
2. Flohr C., Johansson S.G., Wahlgren C.F., Williams H. How atopic is atopic dermatitis?. J Allergy Clin Immunol 2004, 114:150-158.
3. Hanifin J.M. Atopiform dermatitis: do we need another confusing name for atopic dermatitis?. Br J Dermatol 2002, 147:430-432.
4. Novak N., Bieber T., Leung D.Y. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003, 112:128-139.
5. Novak N., Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003, 112:252-262.
6. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venerol (Stock) 1980, 92:44-47.
7. Leung D.Y.M. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997, 107:25-30.
8. Leiferman K.M., Ackerman S.J., Sampson H.A., Haugen H.S., Venencie P.Y., Gleich G.J. Dermal deposition of eosinophilgranule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med 1985, 313:282-285.
9. Simon D., Braathen L.R., Simon H.U. Eosinophils and atopic dermatitis. Allergy 2004, 59:561-570.
10. Schmid-Grendelmeier P., Altznauer F., Fischer B., Bizer C., Straumann A., Menz G., et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002, 169:1021-1027.
11. Kagami S., Kakinuma T., Saeki H., Tsunemi Y., Fujita H., Nakamura K., et al. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol 2003, 134:309-313.
12. Kagami S., Saeki H., Komine M., Kakinuma T., Tsunemi Y., Nakamura K., et al. Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells. Clin Exp Immunol 2005, 141:459-466.
13. Beck L.A., Tancowny B., Brummet M.E., Asaki S.Y., Curry S.L., Penno M.B., et al. Functional analysis of the chemokine receptor CCR3 on airway epithelial cells. J Immunol 2006, 77:3344-3354.
14. Daugherty B.L., Siciliano S.J., DeMartino J.A., Malkowitz L., Sirotina A., Springer M.S. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996, 183:2349-2354.
15. Li L., Xia Y., Nguyen A., Lai Y.H., Feng L., Mosmann T.R., et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999, 162:2477-2487.
16. Banwell M.E., Tolley N.S., Williams T.J., Mitchell T.J. Regulation of human eotaxin-3/CCL26 expression: modulation by cytokines and glucocorticoids. Cytokine 2002, 17:317-323.
17. Kobayashi I., Yamamoto S., Nishi N., Tsuji K., Imayoshi M., Inada S., et al. Regulatory mechanism of Th2 cytokine-induced eotaxin-3 production in bronchial epithelial cells: possible role of interleukin 4 receptor and nuclear factor-kappaB. Ann Allergy Asthma Immunol 2004, 93:390-397.
18. Matsukura S., Stellato C., Plitt J.R., Bickel C., Miura K., Georas S.N., et al. Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells. J Immunol 1999, 163:6876-6883.
19. Walker W., Healey G.D., Hopkin J.M. RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology 2009, 127:256-266.
20. Rankin S.M., Conroy D.M., Williams T.J. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000, 6:20-27.
21. Zeibecoglou K., Ying S., Meng Q., Kay A.B., Robinson D.S., Papageorgiou N. Expression of eotaxin in induced sputum of atopic and nonatopic asthmatics. Allergy 2000, 55:1042-1088.
22. Gleich G.J. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000, 105:651-663.
23. Omoto M., Gu L.H., Sugiura H., Uehara M. Heterogeneity of dermal deposition of eosinophil granule major basic protein in acute lesions of atopic dermatitis. Arch Dermatol Res 2000, 292:51-54.
24. Ring J., Bieber T., Vieluf D., Kunz B., Przybilla B. Atopic eczema, langerhans cells and allergy. Int Arch Allergy Appl Immunol 1991, 94:194-201.
25. Nagai M., Okunishi I. The effect of wasabi rhizome extract on atopic dermatitis-like symptoms in HR-1 hairless mice. J Nutr Sci Vitaminol 2009, 55:195-200.
26. Hossny E., Aboul-Magd M., Bakr S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy 2001, 56:996-1002.
27. Jahnz-Rozyk K., Targowski T., Paluchowska E., Owczarek W., Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005, 60:685-688.
28. Kaburagi Y., Shimada Y., Nagaoka T., Hasegawa M., Takehara K., Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1a, MIP-1b, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res 2001, 293:350-355.
29. Smith H., Cook R.M. Immunopharmacology of Eosinophils 1993, Academic Press, San Diego, CA.
30. Brown J.R., Kleimberg J., Marini M., Sun G., Bellini A., Mattoli S. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin Exp Immunol 1998, 114:137-146.
31. Ravensberg A.J., Ricciardolo F.L., van Schadewijk A., Rabe K.F., Sterk P.J., Hiemstra P.S., et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol 2005, 115:779-785.
32. Berkman N., Ohnona S., Chung F.K., Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001, 24:682-687.
33. Pope S.M., Zimmermann N., Stringer K.F., Karow M.L., Rothenberg M.E. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol 2005, 175:5341-5350.
34. Broide D., Sriramarao P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 2001, 179:163-172.
35. Weber C., Kitayama J., Springer T.A. Differential regulation of β1 and β2 integrin avidity by chemoattractants in eosinophils. Proc Natl Acad Sci USA 1996, 93:10939-10944.
36. Zhu Z., Zheng T., Homer R.J., Kim K.Y., Chen N.Y., Cohn L., et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004, 304:1678-1682.
37. Meyer-Hoffert U., Lezcano-Meza D., Bartels J., Montes-Vizuet A.R., Schröder J.M., Teran L.M. Th2- and to a lesser extent Th1-type cytokines upregulate the production of both CXC (IL-8 and gro-alpha) and CC (RANTES, eotaxin, eotaxin-2, MCP-3 and MCP-4) chemokines in human airway epithelial cells. Int Arch Allergy Immunol 2003, 131:264-271.
38. Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis: eosinophil granule proteins as markers of disease activity. Allergy 1993, 48:1-5.
39. Cheng J.F., Ott N.L., Peterson E.A., George T.J., Hukee M.J., Gleich G.J., et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 1997, 99:683-692.
40. Pucci N., Lombardi E., Novembre E., Farina S., Bernardini R., Rossi E., et al. Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 2000, 105:353-357.
41. Yawalkar N., Uguccioni M., Scharer J., Braunwalder J., Karlen S., Dewald B., et al. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol 1999, 113:43-48.
42. Frank M.M. Urticaria and angioedema. Cecil Textbook of Medicine 2000, 1440-1445. WB Saunders, Philadelphia. 21st ed. L. Goldman, J.C. Bennett (Eds.).
43. Feltis B.N., Reid D.W., Ward C., Walters E.H. BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and b2agonist. Respirology 2004, 9:507-513.
44. Tateno H., Nakamura H., Minematsu N., Nakajima T., Takahashi S., Nakamura M., et al. Plasma eotaxin level and severity of asthma treated with corticosteroid. Respir Med 2004, 98:782-790.
45. Shinkai A., Yoshisue H., Koike M., Shoji E., Nakagawa S., Saito A., et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999, 163:1602-1610.
46. Watanabe K., Jose P.J., Rankin S.M. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J Immunol 2002, 168:1911-1918.